Weight Loss & Metabolic Research Peptides
The GLP-1 (glucagon-like peptide-1) receptor agonist class has generated more clinical research interest in the past five years than any other category of metabolic compounds. Originally developed for type 2 diabetes management, these peptides consistently demonstrate significant body weight reduction in clinical trials — and a growing number of researchers are studying their mechanisms, receptor selectivity, and comparative efficacy.
QSC (Qingdao Sigma Chemical) supplies the complete GLP-1 research landscape at ≥99% HPLC purity with Janoshik COA. All compounds are available at qscpeptide.com.
Order Metabolic Peptides from QSC
≥99% HPLC purity. Janoshik COA. 8-region domestic shipping.
Browse Metabolic Compounds →Semaglutide
CAS 910463-68-2 · MW 4113.58 Da · GLP-1 receptor agonist
Semaglutide is the most extensively studied GLP-1 receptor agonist in clinical research, forming the basis of Ozempic (diabetes) and Wegovy (obesity). The STEP clinical trial programme demonstrated mean body weight reductions of 15–17% over 68 weeks in participants with BMI ≥30. Semaglutide acts by delaying gastric emptying, suppressing appetite via hypothalamic GLP-1 receptors, and improving insulin secretion in a glucose-dependent manner. Its 168-hour half-life (from fatty acid conjugation) enables once-weekly dosing in clinical studies.
Tirzepatide
CAS 2023788-19-2 · MW 4813.48 Da · GLP-1/GIP dual agonist
Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a dual mechanism that produces superior metabolic effects compared to GLP-1 monotherapy. The SURMOUNT trial programme reported mean weight reductions of 20–22% at the highest dose, with cardiovascular benefit data also emerging. The GIP receptor component appears to improve adipocyte insulin sensitivity and reduce nausea compared to pure GLP-1 agonism, making it better tolerated in research settings.
Retatrutide
CAS 2381089-83-2 · Triple agonist: GLP-1 + GIP + Glucagon receptor
Retatrutide represents the cutting edge of metabolic peptide research. The addition of glucagon receptor agonism to the GLP-1/GIP dual mechanism increases energy expenditure (thermogenesis) alongside appetite suppression — a mechanism with no equivalent in approved pharmaceuticals. Phase 2 trials reported mean body weight reductions of 24–26% at 24 weeks, making it the highest-efficacy compound in preclinical or clinical research to date. QSC is one of the few suppliers with verified ≥99% purity retatrutide in consistent stock.
Comparison: GLP-1 Compound Class
| Compound | Receptors | Mean Weight Reduction* | Half-life | Route |
|---|---|---|---|---|
| Semaglutide | GLP-1 | 15–17% | ~168h | SC |
| Tirzepatide | GLP-1 + GIP | 20–22% | ~120h | SC |
| Retatrutide | GLP-1 + GIP + GCG | 24–26% | ~90h | SC |
| Survodutide | GLP-1 + Glucagon | ~18% | ~168h | SC |
| Cagrilintide | Amylin receptor | ~8–10% (monotherapy) | ~7 days | SC |
| Orforglipron | GLP-1 (oral) | ~15% | ~12h | Oral |
*Data from published Phase 2/3 clinical trials. Not predictive of individual research outcomes.
Research Use Only. All compounds referenced are for laboratory research purposes only. Not for human consumption. QSC Wellness is an official information resource for Qingdao Sigma Chemical Co., Ltd.